GLAB — Gemina Laboratories Balance Sheet
0.000.00%
- CA$34.46m
- CA$34.70m
Annual balance sheet for Gemina Laboratories, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.898 | 1.17 | 0.083 | 0.001 | 0.001 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.004 | 0.178 | 0.386 | 0.038 | 0.035 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2.45 | 1.38 | 0.563 | 0.093 | 0.106 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.046 | 0.041 | 0.318 | 0.369 | 0.315 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2.53 | 1.42 | 1.87 | 1.46 | 1.44 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.33 | 0.47 | 1.75 | 2.84 | 5.7 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.37 | 0.476 | 1.95 | 3.04 | 5.87 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.16 | 0.944 | -0.072 | -1.59 | -4.44 |
| Total Liabilities & Shareholders' Equity | 2.53 | 1.42 | 1.87 | 1.46 | 1.44 |
| Total Common Shares Outstanding |